Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

RegulatoryModzatinibPositive

AI Analysis

Summary

Aclaris Therapeutics has received Fast Track Designation from the FDA for Modzatinib (ATI-2138) in the treatment of moderate to severe lichen planus, which may accelerate the drug's development and review pathway.

Outcome Details

Fast Track Designation granted

Importance:5/10

Sentiment:

0.70

Fast Track DesignationDermatologyLichen PlanusRegulatory

Related Companies

$ACRS

Read the original article

Published by GlobeNewswire Pharma on August 6, 2026 8:35 PM

Read Original